{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:42:33Z","timestamp":1790494953507,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2018\/SKK08\/PERDANA\/03\/1"],"award-info":[{"award-number":["FRGS\/1\/2018\/SKK08\/PERDANA\/03\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jns.2021.117485","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:22:44Z","timestamp":1620818564000},"page":"117485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The potential role of miRNA therapies in spinal muscle atrophy"],"prefix":"10.1016","volume":"427","author":[{"given":"Gayatri","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syahril","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agus Iwan","family":"Foead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Wai Yeng","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117485_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D\u2019Amico","year":"2011","journal-title":"Orphan. J. Rare Diseas."},{"issue":"16","key":"10.1016\/j.jns.2021.117485_bb0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.4155\/fmc.12.131","article-title":"SMN-inducing compounds for the treatment of spinal muscular atrophy","volume":"4","author":"Lorson","year":"2012","journal-title":"Future Med. Chem."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am. J. Med. Genet."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0020","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am. J. Med. Genet. Part A."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"issue":"8","key":"10.1016\/j.jns.2021.117485_bb0035","doi-asserted-by":"crossref","first-page":"18312","DOI":"10.3390\/ijms160818312","article-title":"A perturbed MicroRNA expression pattern characterizes embryonic neural stem cells derived from a severe mouse model of spinal muscular atrophy (SMA)","volume":"16","author":"Luchetti","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2021.117485_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl. Clin. Genet."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0045","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J. Clin. Med."},{"issue":"7006","key":"10.1016\/j.jns.2021.117485_bb0050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature."},{"key":"10.1016\/j.jns.2021.117485_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/2230-973X.167646","article-title":"An overview of viral and nonviral delivery systems for microRNA","volume":"5","author":"Yang","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0065","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0070","article-title":"Altered levels of MicroRNA-9,-206, and-132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy","volume":"5","author":"Catapano","year":"2016","journal-title":"Mol Ther - Nucleic Acids."},{"issue":"19","key":"10.1016\/j.jns.2021.117485_bb0075","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1093\/hmg\/ddz142","article-title":"AAV9-mediated delivery of miR-23a reduces disease severity in Smn2B\/-SMA model mice","volume":"28","author":"Kaifer","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.50848","article-title":"Multifaceted roles of microRNAs: from motor neuron generation in embryos to degeneration in spinal muscular atrophy","volume":"8","author":"Chen","year":"2019","journal-title":"Elife."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jcmm.13450","article-title":"miRNA in spinal muscular atrophy pathogenesis and therapy","volume":"22","author":"Magri","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ncrna.2018.12.001","article-title":"Dysregulation of microRNA metabolism in motor neuron diseases: Novel biomarkers and potential therapeutics","volume":"4","author":"De Paola","year":"2019","journal-title":"Non-coding RNA Res."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biomedicines8020021","article-title":"Circulating myomirs as potential biomarkers to monitor response to nusinersen in pediatric SMA patients","volume":"8","author":"Bonanno","year":"2020","journal-title":"Biomedicines."},{"key":"10.1016\/j.jns.2021.117485_bb0100","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.82738","article-title":"Therapeutic implication of miRNA in human disease","author":"Walayat","year":"2019","journal-title":"Antisense Therapy."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0105","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/cells9071698","article-title":"Current status of microRNA-based therapeutic approaches in neurodegenerative disorders","volume":"9","author":"Paul","year":"2020","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/mps4010010","article-title":"Recent advances in miRNA delivery systems","volume":"4","author":"Dasgupta","year":"2021","journal-title":"Methods Protoc."},{"issue":"14","key":"10.1016\/j.jns.2021.117485_bb0115","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","article-title":"A novel nuclear structure containing the survival of motor neurons protein","volume":"15","author":"Liu","year":"1996","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/bmme.1997.2590","article-title":"Expression study of survival motor neuron gene in human fetal tissues","volume":"61","author":"Novelli","year":"1997","journal-title":"Biochem. Mol. Med."},{"issue":"9","key":"10.1016\/j.jns.2021.117485_bb0125","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/gt.2017.46","article-title":"Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy","volume":"24","author":"Jablonka","year":"2017","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim. Biophys. Acta - Gene Regulat. Mechan."},{"issue":"161","key":"10.1016\/j.jns.2021.117485_bb0135","article-title":"The role of RNA binding proteins for local mRNA translation: implications in neurological disorders","volume":"6","author":"Thelen","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.jns.2021.117485_bb0140","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jns.2021.117485_bb0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0150","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/joa.12419","article-title":"Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy","volume":"228","author":"Powis","year":"2016","journal-title":"J. Anat."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/dneu.22111","article-title":"Dynamics of survival of motor neuron (SMN) protein interaction with the mRNA-binding protein IMP1 facilitates its trafficking into motor neuron axons","volume":"74","author":"Fallini","year":"2014","journal-title":"Dev Neurobiol."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1083\/jcb.200703187","article-title":"Defective Ca2+ channel clustering in axon terminals disturbs excitability in motoneurons in spinal muscular atrophy","volume":"179","author":"Jablonka","year":"2007","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2044-5040-3-24","article-title":"Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy","volume":"3","author":"Boyer","year":"2013","journal-title":"Skelet. Muscle"},{"issue":"18","key":"10.1016\/j.jns.2021.117485_bb0175","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1093\/hmg\/ddu189","article-title":"Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics","volume":"23","author":"Bricceno","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"20","key":"10.1016\/j.jns.2021.117485_bb0180","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","article-title":"Early heart failure in the SMN\u03947 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery","volume":"19","author":"Bevan","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0185","doi-asserted-by":"crossref","first-page":"34635","DOI":"10.1038\/srep34635","article-title":"Survival motor neuron (SMN) protein is required for normal mouse liver development","volume":"6","author":"Szunyogova","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jns.2021.117485_bb0190","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/acn3.50855","article-title":"Abnormal fatty acid metabolism is a core component of spinal muscular atrophy","volume":"6","author":"Deguise","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joa.12546","article-title":"Survival of motor neuron protein is required for normal postnatal development of the spleen","volume":"230","author":"Thomson","year":"2017","journal-title":"J. Anat."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2566","article-title":"Bone loss in survival motor neuron (Smn\u2212\/\u2212 SMN2) genetic mouse model of spinal muscular atrophy","volume":"219","author":"Shanmugarajan","year":"2009","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.jns.2021.117485_bb0210","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2021.117485_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","author":"Butchbach","year":"2016","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0220","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0225","first-page":"1","article-title":"Mutation spectrum of survival motor neuron gene in spinal muscular atrophy","volume":"3","author":"Rad","year":"2017","journal-title":"J. Down Syndr. Chromosom. Abnorm."},{"issue":"6","key":"10.1016\/j.jns.2021.117485_bb0230","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000530","article-title":"Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy","volume":"6","author":"Cusc\u00f3","year":"2020","journal-title":"Neurol Genet."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0235","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightcycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0240","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum. Genet."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.jns.2021.117485_bb0250","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","article-title":"New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations","volume":"12","author":"Ogino","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"issue":"8","key":"10.1016\/j.jns.2021.117485_bb0255","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J. Child Neurol."},{"issue":"5164","key":"10.1016\/j.jns.2021.117485_bb0260","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.7910982","article-title":"De novo and inherited deletions of the 5q13 region in spinal muscular atrophies","volume":"264","author":"Melki","year":"1994","journal-title":"Science."},{"key":"10.1016\/j.jns.2021.117485_bb0265","first-page":"9.27.1","article-title":"Spinal muscular atrophy: overview of molecular diagnostic approaches","volume":"88","author":"Prior","year":"2016","journal-title":"Curr. Protoc. Hum. Genet."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0270","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.jns.2021.117485_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201764","article-title":"A new biomarker candidate for spinal muscular atrophy: identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein","volume":"13","author":"Otsuki","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0280","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/bbrc.1995.2135","article-title":"Survival motor-neuron gene transcript analysis in muscles from spinal muscular-atrophy patients","volume":"213","author":"Gennarelli","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0285","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/17460441.2.4.437","article-title":"Drug discovery for spinal muscular atrophy","volume":"2","author":"Wirth","year":"2007","journal-title":"Expert Opin. Drug Discovery"},{"issue":"23","key":"10.1016\/j.jns.2021.117485_bb0290","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","article-title":"Disease mechanisms and therapeutic approaches in spinal muscular atrophy","volume":"35","author":"Tisdale","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2021.117485_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nmd.2019.06.514","article-title":"P.352Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): results from the SHINE study","volume":"29","author":"Kirschner","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","article-title":"Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever","volume":"9","author":"Mahajan","year":"2019","journal-title":"Int J Appl Basic Med Res."},{"issue":"12\u2013a","key":"10.1016\/j.jns.2021.117485_bb0305","article-title":"Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"15","key":"10.1016\/j.jns.2021.117485_bb0310","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"issue":"72","key":"10.1016\/j.jns.2021.117485_bb0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2021.117485_bb0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jns.2021.117485_bb0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fneur.2020.00045","article-title":"The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs","volume":"11","author":"Hensel","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.117485_bb0330","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.14974","article-title":"Combinatorial treatment for spinal muscular atrophy","author":"Poletti","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2021.117485_bb0335","series-title":"FDA Approves Innovative Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy, a Rare Disease and Leading Genetic Cause of Infant Mortality","year":"2020"},{"key":"10.1016\/j.jns.2021.117485_bb0340","unstructured":"Officer M. Media & Investor Release. 2020;1\u20135."},{"key":"10.1016\/j.jns.2021.117485_bb0345","doi-asserted-by":"crossref","first-page":"592234","DOI":"10.3389\/fphar.2020.592234","article-title":"Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment","volume":"11","author":"Menduti","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0350","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.jns.2021.117485_bb0355","first-page":"585","article-title":"New prospects fot the treatment of Spinal Muscular Atrophy","volume":"9","author":"Poleszak","year":"2019","journal-title":"J. Educ. Health Sport"},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0360","first-page":"261","article-title":"CK-2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy","volume":"17","author":"Rudnicki","year":"2016","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.jns.2021.117485_bb0365","series-title":"All Disease Areas All Phases","first-page":"2","volume":"093","author":"Biogen","year":"2021"},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019932","article-title":"Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)","volume":"8","author":"Stam","year":"2018","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jns.2021.117485_bb0375","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/labinvest.3700163","article-title":"Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients","volume":"84","author":"Arnold","year":"2004","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jns.2021.117485_bb0380","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2021.117485_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00478","article-title":"The potential for microRNA therapeutics and clinical research","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0390","first-page":"3907","article-title":"Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology","volume":"8","author":"McKiernan","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"24","key":"10.1016\/j.jns.2021.117485_bb0395","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.febslet.2014.11.013","article-title":"MiR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3","volume":"588","author":"Huang","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jns.2021.117485_bb0400","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12896-018-0421-6","article-title":"Total RNA extraction from tissues for microRNA and target gene expression analysis: not all kits are created equal","volume":"18","author":"Brown","year":"2018","journal-title":"BMC Biotechnol."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0405","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jconrel.2013.09.015","article-title":"Progress in microRNA delivery","volume":"172","author":"Zhang","year":"2013","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0410","doi-asserted-by":"crossref","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of micro RNA therapeutics is coming of age","volume":"6","author":"Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jns.2021.117485_bb0415","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jns.2021.117485_bb0420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.kjms.2013.12.007","article-title":"Survival of motor neuron protein downregulates miR-9 expression in patients with spinal muscular atrophy","volume":"30","author":"Wang","year":"2014","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"9","key":"10.1016\/j.jns.2021.117485_bb0425","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Molec. Therapy - Nucleic Acids"},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0430","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"issue":"17","key":"10.1016\/j.jns.2021.117485_bb0435","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/hmg\/ddx230","article-title":"Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy","volume":"26","author":"Sison","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"23","key":"10.1016\/j.jns.2021.117485_bb0440","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1093\/hmg\/ddu350","article-title":"SMN regulates axonal local translation via miR-183\/mTOR pathway","volume":"23","author":"Kye","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.jns.2021.117485_bb0445","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v29.i6.20","article-title":"In vivo delivery aspects of miRNA, shRNA and siRNA","volume":"29","author":"Khatri","year":"2012","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jns.2021.117485_bb0450","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.05.014","article-title":"MicroRNA delivery for regenerative medicine","volume":"88","author":"Peng","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.jns.2021.117485_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128560","article-title":"Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model","volume":"10","author":"Valsecchi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2021.117485_bb0460","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fgene.2015.00340","article-title":"Transfection of microRNA mimics should be used with caution","volume":"6","author":"Jin","year":"2015","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.jns.2021.117485_bb0465","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/mt.2016.39","article-title":"Argonaute 2-dependent regulation of gene expression by single-stranded miRNA mimics","volume":"24","author":"Matsui","year":"2016","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0470","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/stem.2233","article-title":"MiR-375 is essential for human spinal motor neuron development and may be involved in motor neuron degeneration","volume":"34","author":"Bhinge","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.jns.2021.117485_bb0475","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1242\/jcs.056812","article-title":"A putative role for microRNA-205 in mammary epithelial cell progenitors","volume":"123","author":"Greene","year":"2010","journal-title":"J. Cell Sci."},{"issue":"16","key":"10.1016\/j.jns.2021.117485_bb0480","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1089\/scd.2012.0650","article-title":"Sodium butyrate promotes generation of human induced pluripotent stem cells through induction of the miR302\/367 cluster","volume":"22","author":"Zhang","year":"2013","journal-title":"Stem Cells Dev."},{"issue":"25","key":"10.1016\/j.jns.2021.117485_bb0485","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/onc.2014.274","article-title":"MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets","volume":"34","author":"Su","year":"2015","journal-title":"Oncogene."},{"issue":"11","key":"10.1016\/j.jns.2021.117485_bb0490","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/hmg\/ddw084","article-title":"Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy","volume":"25","author":"Wertz","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.jns.2021.117485_bb0495","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jns.2021.117485_bb0500","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-05-3428","article-title":"Defective p53 response and apoptosis associated with an ataxia-telangiectasia-like phenotype","author":"Gueven","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jns.2021.117485_bb0505","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2014.10.031","article-title":"Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors","volume":"81","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jns.2021.117485_bb0510","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","article-title":"Recent progress in microRNA-based delivery systems for the treatment of human disease","volume":"1","author":"Fu","year":"2019","journal-title":"ExRNA."},{"key":"10.1016\/j.jns.2021.117485_bb0515","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","article-title":"Current prospects for RNA interference-based therapies","volume":"12","author":"Davidson","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0520","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6782653","article-title":"Current progress on microRNA-based gene delivery in the treatment of osteoporosis and osteoporotic fracture","author":"Sun","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.jns.2021.117485_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2016.00129","article-title":"Getting miRNA therapeutics into the target cells for neurodegenerative diseases: a mini-review","author":"Wen","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jns.2021.117485_bb0530","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddz148","article-title":"Next-generation AAV vectors - don\u2019t judge a virus (only) by its cover","author":"Domenger","year":"2019","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0535","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.addr.2006.03.006","article-title":"Viral vectors for gene delivery in tissue engineering","volume":"58","author":"Zhang","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jns.2021.117485_bb0540","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jns.2021.117485_bb0545","series-title":"Adeno-Associated Virus (AAV) Vector Gene Therapy - From Idea to IND Early Phase Product Development \u2013What to Consider?","first-page":"1","author":"Outsourcing","year":"2021"},{"issue":"13","key":"10.1016\/j.jns.2021.117485_bb0550","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1128\/JVI.77.13.7689-7695.2003","article-title":"Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo","volume":"77","author":"Ehrhardt","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0555","first-page":"3","article-title":"Non-viral and viral vectors for gene therapy","volume":"51","author":"Boulaiz","year":"2005","journal-title":"Cell. Mol. Biol."},{"issue":"17","key":"10.1016\/j.jns.2021.117485_bb0560","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.biomaterials.2005.12.029","article-title":"Modified montmorillonite as vector for gene delivery","volume":"27","author":"Lin","year":"2006","journal-title":"Biomaterials."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0565","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2230-973X.104388","article-title":"Nonviral gene delivery system","volume":"2","author":"Yang","year":"2012","journal-title":"Int. J. Pharm. Investig."},{"issue":"31","key":"10.1016\/j.jns.2021.117485_bb0570","doi-asserted-by":"crossref","first-page":"30675","DOI":"10.18632\/oncotarget.5169","article-title":"Progresses towards safe and efficient gene therapy vectors","volume":"6","author":"Chira","year":"2015","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0575","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v28.i4.20","article-title":"Lipid nanocarriers: influence of lipids on product development and pharmacokinetics","volume":"28","author":"Pathak","year":"2011","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0580","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1166\/jnn.2014.9080","article-title":"Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery","volume":"14","author":"Mallick","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.jns.2021.117485_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055214","article-title":"On measuring miRNAs after transient transfection of mimics or antisense inhibitors","author":"Thomson","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jns.2021.117485_bb0590","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2015.111","article-title":"Dual TNF-\u03b1\/IL-12p40 interference as a strategy to protect against colitis based on miR-16 precursors with macrophage targeting vectors","volume":"23","author":"Huang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jns.2021.117485_bb0595","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1196\/annals.1359.012","article-title":"Endo-Porter: a novel reagent for safe, effective delivery of substances into cells","volume":"1058","author":"Summerton","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.jns.2021.117485_bb0600","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/zeb.2009.0589","article-title":"Effective polyethyleneimine-mediated gene transfer into zebrafish cells","volume":"6","author":"Ouyang","year":"2009","journal-title":"Zebrafish."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2003.11.023","article-title":"Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications","volume":"33","author":"Dalby","year":"2004","journal-title":"Methods."},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0610","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1261\/rna.2252206","article-title":"Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons","volume":"12","author":"T\u00f6nges","year":"2006","journal-title":"RNA."},{"issue":"18","key":"10.1016\/j.jns.2021.117485_bb0615","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1523\/JNEUROSCI.0183-10.2010","article-title":"Transfection techniques for neuronal cells","volume":"30","author":"Karra","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2021.117485_bb0620","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.jns.2021.117485_bb0625","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1039\/C8TB02946F","article-title":"Non-viral nanocarriers for intracellular delivery of microRNA therapeutics","volume":"7","author":"Bai","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"6","key":"10.1016\/j.jns.2021.117485_bb0630","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1634\/stemcells.19-6-492","article-title":"High efficiency electroporation of human umbilical cord blood CD34 + hematopoietic precursor cells","volume":"19","author":"Wu","year":"2001","journal-title":"Stem Cells"},{"issue":"9","key":"10.1016\/j.jns.2021.117485_bb0635","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0301-5629(96)00089-0","article-title":"A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective","volume":"22","author":"Miller","year":"1996","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.jns.2021.117485_bb0640","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2016.08.005","article-title":"Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs","volume":"238","author":"Mullick Chowdhury","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jns.2021.117485_bb0645","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/srep05417","article-title":"Microinjection free delivery of miRNA inhibitor into zygotes","volume":"4","author":"Joo","year":"2014","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jns.2021.117485_bb0650","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"Electr. J. Int. Fed. Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0655","first-page":"20","volume":"173","author":"Bartel","year":"2019","journal-title":"Metazoan MicroRNAs."},{"key":"10.1016\/j.jns.2021.117485_bb0660","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: challenges and strategies","volume":"81","author":"Chen","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0665","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00018-015-2093-x","article-title":"microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases","volume":"73","author":"Basak","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.jns.2021.117485_bb0670","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.cell.2010.03.039","article-title":"Characterizing light-regulated retinal MicroRNAs reveals rapid turnover as a common property of neuronal MicroRNAs","volume":"141","author":"Krol","year":"2010","journal-title":"Cell."},{"key":"10.1016\/j.jns.2021.117485_bb0675","article-title":"MicroRNAs in Neurotoxicity","volume":"870150","author":"Kaur","year":"2012","journal-title":"J. Toxico."},{"issue":"6","key":"10.1016\/j.jns.2021.117485_bb0680","doi-asserted-by":"crossref","DOI":"10.1038\/nn.3113","article-title":"An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration","volume":"15","author":"Lehmann","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2021.117485_bb0685","first-page":"1","article-title":"MiR-21 in extracellular vesicles leads to neurotoxicity via TLR7 signaling in SIV neurological disease","author":"Yelamanchili","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jns.2021.117485_bb0690","series-title":"miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington\u2019s Disease Monkey Neural Cells","first-page":"15","author":"Kunkanjanawan","year":"2016"},{"issue":"7","key":"10.1016\/j.jns.2021.117485_bb0695","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13238-015-0168-y","article-title":"Secreted miR-34a in astrocytic shedding vesicles enhanced the vulnerability of dopaminergic neurons to neurotoxins by targeting Bcl-2","volume":"6","author":"Mao","year":"2015","journal-title":"Protein Cell."},{"key":"10.1016\/j.jns.2021.117485_bb0700","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jns.2021.117485_bb0705","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:55:00Z","timestamp":1758383700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21001799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":141,"alternative-id":["S0022510X21001799"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117485","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of miRNA therapies in spinal muscle atrophy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117485"}}